1. 10 PHILADELPHIA CHROMOSOME MOSAICISM DUE TO ADDITIONAL CYTOGENETIC ABNORMALITIES IN CHRONIC MYELOID LEUKEMIA MIGHT ADVERSELY AFFECT PROGNOSIS AND RESPONSE TO IMATINIB. (1st March 2007) Authors: Landstrom, A.; Ketterling, R.; Knudson, R.; Dewald, G.; Tefferi, A. Journal: Journal of investigative medicine Issue: Volume 55:Number 2(2007) Page Start: S349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 152 BONE MARROW CONVENTIONAL KARYOTYPING AND FLUORESCENCE IN SITU HYBRIDIZATION (FISH): DEFINING AN EFFECTIVE UTILIZATION STRATEGY FOR THE EVALUATION OF MYELODYSPLASTIC SYNDROME (MDS). (April 2015) Authors: He, R.; Wiktor, A.E.; Kurtin, P.J.; Van Dyke, D.L.; Tefferi, A.; Patnaik, M.S.; Ketterling, R.P.; Hanson, C.A. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS. (23rd June 2022) Authors: Kiladjian, J.-J.; Tefferi, A.; Passamonti, F.; Vannucchi, A.; Talpaz, M.; Cervantes, F.; Harrison, C. N.; Mesa, R. A.; Mascarenhas, J.; Schaap, N.; Verstovsek, S.; Devos, T.; Rose, S.; Zhang, J.; Sy, O.; Pardanani, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS. (23rd June 2022) Authors: Johnson, I.; McCullough, K.; Farrukh, F.; Al-Kali, A.; Alkhateeb, H.; Begna, K.; Mangaonkar, A.; Litzow, M.; Hogan, W.; Shah, M.; Patnaik, M.; Pardanani, A.; Tefferi, A.; Gangat, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P775: CLINICAL OUTCOMES AND SOCIOECONOMIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE UNITED STATES USING THE NATIONAL CANCER DATABASE: 2004-2017. (23rd June 2022) Authors: Mclaughlin, N.; Ruan, G.; Wudhikarn, K.; Al-Kali, A.; Tefferi, A.; Gangat, N.; Go, R.; Patnaik, M.; Shah, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Issue 6 (November 2016) Authors: Barbui, T.; Thiele, J.; Gisslinger, H.; Finazzi, G.; Vannucchi, A.M.; Tefferi, A. Journal: Blood reviews Issue: Volume 30:Issue 6(2016:Nov.) Page Start: 453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: SOMATIC TP53 SINGLE NUCLEOTIDE VARIANTS, INDELS AND COPY NUMBER ALTERATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML). (May 2023) Authors: Gurney, M.; Mangaonkar, A.; Lasho, T.; Finke, C.; Al-Kali, A.; Gangat, N.; Shah, M.; Alkhateeb, H.; Tefferi, A.; Komrokji, R.; Viswanatha, D.; Reichard, K.; Al Ali, N.; Padron, E.; Patnaik, M. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗